A new Boxed Warning will be required in the prescribing information for several insomnia medications following reports of serious injuries and deaths associated with complex sleep behaviors where patients engaged in activities while not fully awake.
Higher-than-recommended dosages were commonly prescribed to women who were new zolpidem users.
Predictors of neurodegeneration from idiopathic REM sleep behavior disorder (iRBD) have been identified.
Eisai and Imbrium Therapeutics announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lemborexant, an investigational insomnia treatment.
This research supports the legitimacy of digital cognitive behavioral therapy as a treatment method for individuals with insomnia.
Digital cognitive behavioral therapy is effective in improving functional health, psychological well-being, and sleep-related quality of life in people reporting insomnia.
Researchers confirmed the existence of a direct link between clock genes and 2 comorbid diseases, as well as the genetic predisposition for alcohol abuse.
The authors argue that identifying and treating sleep disorders during early stages may have a positive impact on outcomes in psychiatric patients.
Non-smoking adolescents with tobacco smoke exposure have increased risk for TSE-related symptoms.
On the basis of these findings, researchers recommended that “[f]atigue should be evaluated whenever there is clinical suspicion of overlap syndrome.”
